For the quarter ending 2026-03-31, SLNCF has $115,123K in assets. $65,721K in debts. $5,657K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 5,657 | 11,277 | 82,031 | |
| Short-term investments | 64,421 | 73,837 | 20,161 | |
| R&d benefit receivable | 22,216 | 22,007 | 22,152 | |
| Other current assets | 10,558 | 11,537 | 9,260 | |
| Trade receivables | 0 | 0 | 28 | |
| Total current assets | 102,852 | 118,658 | 133,632 | |
| Property, plant and equipment | 1,396 | 1,581 | 1,655 | |
| Operating lease right-of-use asset | 142 | 167 | 192 | |
| Goodwill | 10,358 | 10,621 | 10,612 | |
| Intangible assets | - | 288 | - | |
| Other intangible assets | 248 | - | 300 | |
| Other long-term assets | 127 | 127 | 399 | |
| Total assets | 115,123 | 131,442 | 146,790 | |
| Contract liabilities | 0 | 168 | 301 | |
| Trade and other payables | 10,367 | 13,356 | 16,993 | |
| Operating lease liabilities, current | 93 | 89 | 85 | |
| Total current liabilities | 10,460 | 13,613 | 17,379 | |
| Contract liabilities | 55,218 | 55,454 | 55,251 | |
| Operating lease liabilities | 43 | 71 | 97 | |
| Total liabilities | 65,721 | 69,138 | 72,727 | |
| Ordinary shares - par value gbp 0.05 per share 141,703,840 shares issued at march 31, 2026 (december 31, 2025 141,701,848) | 10,290 | 10,290 | 10,290 | |
| Additional paid-in capital | 620,006 | 617,562 | 617,648 | |
| Accumulated deficit | -577,526 | -562,572 | -550,802 | |
| Accumulated other comprehensive loss | -3,368 | -2,976 | -3,073 | |
| Total shareholders' equity | 49,402 | 62,304 | 74,063 | |
| Total liabilities and shareholders' equity | 115,123 | 131,442 | 146,790 | |
Silence Therapeutics plc (SLNCF)
Silence Therapeutics plc (SLNCF)